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physical activity in patients with moderate
chronic obstructive pulmonary disease - a
randomized, multicenter, double-blind,
placebo-controlled study
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Background: Indacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects
of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured
physical activity during treatment with indacaterol 150 μg and matched placebo.
Methods: We performed a randomized, three-period, cross-over study (21 days of treatment separated by two
wash-out periods of 13 days) with indacaterol 150 μg or matching placebo and tiotropium 18 μg. Lung function was
assessed by body plethysmography and spirometry. Physical activity was measured for one week by a multisensory
armband at the end of both treatment periods with indacaterol/matched placebo. The primary endpoint was peak
inspiratory capacity at the end of each treatment period.
Results: 129 patients (mean age, 61 years; mean post-bronchodilator FEV1, 64%), were randomized and 110 patients
completed the study. Peak inspiratory capacity was 0.22 L greater with Indacaterol at day 21 compared to placebo
(p < 0.001). Similar results were observed for tiotropium. Both bronchodilators also significantly improved other
parameters of lung hyperinflation compared with placebo. All parameters of physical activity were significantly
increased during treatment with indacaterol versus placebo.
Conclusions: Indacaterol 150 μg improved lung hyperinflation in patients with moderate COPD, which was associated
with an increase of physical activity.
Trial registration: ClinicalTrials.gov registration number: NCT01012765.
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Chronic obstructive pulmonary disease (COPD) is charac-
terized by persistent airflow limitation that results in air
trapping and lung hyperinflation [1-3]. Lung hyperinfla-
tion negatively affects various physiological responses to
exercise and is thought to be one of the main mechanisms* Correspondence: h.watz@pulmoresearch.de
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unless otherwise stated.leading to exertional dyspnea, exercise intolerance, and,
consequently, reduced physical activity in daily life [3,4].
Significant limitations of physical activity are already
present in patients with moderate COPD [5,6]. This obser-
vation might be of clinical relevance as reduced physical
activity is related to hospitalizations [7-9], impaired health-
related quality of life [10], muscle deconditioning [10,11],
and all-cause mortality in patients with COPD [8,12,13].
Bronchodilators are central to symptomatic manage-
ment of COPD [1]. Indacaterol is an inhaled ultra-
long-acting β2-agonist providing 24-h bronchodilation
with once-daily dosing in patients with COPD [14].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Watz et al. BMC Pulmonary Medicine 2014, 14:158 Page 2 of 8
http://www.biomedcentral.com/1471-2466/14/158Indacaterol has been demonstrated to improve airflow
limitation, dyspnea, and exercise intolerance in patients
with COPD [14-17].
Less is known about the effects of treatment with
indacaterol on lung hyperinflation and physical activity
in patients with COPD. Rossi and colleagues showed
that a single inhalation of indacaterol 150 μg reduced
lung hyperinflation with treatment effects being slightly
superior to the effects of a single inhalation of tiotro-
pium 18 μg in patients with moderate COPD [18]. How-
ever, it is currently unknown whether these effects on
lung function are sustained over a longer period of time.
In another study, O’Donnell and colleagues evaluated
the effects of indacaterol 300 μg on exercise endurance,
lung hyperinflation, and physical activity in patients with
moderate to severe COPD [17]. While significant im-
provements of exercise endurance time and hyperinfla-
tion during exercise could be observed, there was no
effect on physical activity in that study [17]. This con-
trasts with a recent study demonstrating that open-label
treatment with indacaterol resulted in an improvement
of physical activity in 23 patients with COPD [19]. Ap-
plying a recently published measurement protocol with
a rigorous whole-day measurement of physical activity
[5] we decided to implement an accelerometer-based meas-
urement of physical activity in the present study in order to
evaluate whether an improvement of lung hyperinflation
might also translate into changes of physical activity.
The present study was designed to assess the effects of
indacaterol on lung hyperinflation compared with pla-
cebo and tiotropium, and to measure physical activity
during treatment with indacaterol and matched placebo
in patients with moderate COPD. Some study results
have previously been reported in an abstract [20].
Methods
Patients
Patients eligible for inclusion in this study were male
and female adults aged 40 years or older with a diagnosis
of moderate COPD according to the spirometric classifi-
cation of the “Global Initiative for Chronic Obstructive
Pulmonary Disease” (post-bronchodilator forced expira-
tory volume in one second (FEV1) <80% and ≥50% of
the predicted normal value and a post-bronchodilator
ratio of FEV1 to forced vital capacity (FVC) <70%) and a
smoking history of at least 10 pack years. Key exclusion
criteria were a respiratory tract infection or exacerbation
within 6 weeks prior to study entry, a history of asthma
or any corticosteroid use (inhaled or systemic applica-
tion) within the last three months prior to study entry,
any other concomitant lung disease, or any clinically sig-
nificant condition which in the opinion of investigator
might compromise patient safety or compliance, interfere
with evaluation, or preclude completion of the study.Study design
This was a randomized, multicenter, double-blind, placebo-
controlled, 3-period, cross-over study conducted at 28
specialised respiratory care centres in Germany (Clini-
calTrials.gov registration number: NCT01012765). The
study protocol and all amendments were approved by
the Ethics Committee of the University of Marburg
(126/09A). The study was conducted according to the
ethical principles of the Declaration of Helsinki be-
tween November 2009 and January 2011. All patients
provided written informed consent prior to their par-
ticipation in the study.
Study medications
Following a 2-week run-in, patients were randomised to
the treatment sequences with indacaterol 150 μg q.d. via
single-dose dry powder inhaler (Onbrez® Breezhaler®
inhalation powder; Novartis, Basel, Switzerland) or tio-
tropium 18 μg q.d. via its proprietary single-dose dry
powder inhaler (Spiriva® HandiHaler® inhalation powder;
Boehringer Ingelheim, Ingelheim, Germany) or placebo to
indacaterol via single-dose dry powder inhaler (Breezhaler®
device; Novartis, Basel, Switzerland). This means that
treatment with indacaterol and placebo was double
blinded, whereas treatment with tiotropium was open
label. Each treatment period consisted of 21 days of dosing
separated by 13 days of wash-out. Patients were random-
ized equally to one of six treatment sequences.
Concomitant medications
Patients were provided with a short-acting β2-agonist
(salbutamol) to use as required. Apart from study treat-
ments, no other bronchodilator use was permitted. Long
acting bronchodilators were discontinued prior to ran-
domization with an appropriate washout of two days for




Lung function was measured by body plethysmography
and forced spirometry according to current recommen-
dations [21,22]. Three acceptable measurements had to
be performed and the average values of functional re-
sidual capacity (FRC; intrathoracic gas volume [ITGV])
and inspiratory capacity (IC) were used for calculation of
total lung capacity (TLC). Residual volume was calcu-
lated by subtracting the largest slow vital capacity
assessed during expiration from TLC. Specific airway re-
sistance (sRaw) was measured using the calculation of
the effective specific airway resistance (sReff) [23]. Forced
spirometry manoeuvres were performed after the body
plethysmography measurements. The highest FEV1 and
highest FVC of three acceptable manoeuvres were taken
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the same curve.
Physical activity
Physical activity was measured using the SenseWear
multisensory armband (SenseWear® Armband®; BodyMedia,
Pittsburgh, PA, USA) over a period of one week at the end
of each treatment period as previously described [5]. Phys-
ical activity parameters were steps per day, minutes of at
least moderate physical activity per day, and the average
physical activity level (total daily energy expenditure di-
vided by resting energy expenditure) as previously re-
ported [5]. Validity of the energy-related physical activity
estimates of the multisensory armband has previously
been demonstrated [24,25].
We defined the measurement of physical activity to
be reliable when at least three days of measurement
with a recorded wearing time of at least 22 hours per
day were available, which has previously been shown to
result in an intra-class correlation coefficient of about
0.7 in patients with moderate COPD [5]. An intra-class
correlation coefficient of 0.7 indicates that about 70%
of the variation of physical activity of the group is cap-
tured [5].
Objectives
The primary objective of this study was to demonstrate
the superiority of indacaterol 150 μg q.d. compared to
placebo on peak IC after 21 days of treatment. The key
secondary end-point was non-inferiority of indacaterol
150 μg q.d. compared to open label tiotropium 18 μg q.
d. on peak IC after 21 days and trough IC after 20 days
of treatment. Further secondary endpoints included the
effects of indacaterol and tiotropium compared to pla-
cebo on trough and peak FRC, RV, RV/TLC ratio, sRaw,
and FEV1. Peak values were defined as the individual
highest value measured at 30, 120, 180 and 240 min post
inhalation of study medication at day 21. Trough values
were assessed 30 min prior inhalation of study drug at
day 21. Exploratory endpoints were steps per day, mi-
nutes of at least moderate activity, and the physical ac-
tivity level.
Sample size and statistical methods
A treatment difference of 150 mL (with a standard devi-
ation of 400 mL) in inspiratory capacity at day 21 was
prespecified for non-inferiority. Based on this, a sample
size of 80 evaluable patients was needed to detect this
difference as statistically significant at the 2.5% level
(one-sided) with 90% power. This sample size would
provide 90% power for testing superiority, assuming a
superiority margin of 300 mL (5% significance level, two
sided). An assumed drop-out rate of 30% gave a mini-
mum sample size of 125 patients.Two patient populations were defined for analysis:
1) full-analysis-set population (n = 129), which comprised
all randomized patients who received at least one dose of
study drug during at least one study period; and 2) safety
population (n = 129), which comprised patients who re-
ceived at least one dose of study drug during at least one
study period, and who had at least one safety assessment
after baseline.
The analysis was performed comparing treatments
with respect to the efficacy variables in an analysis of
variance (ANOVA) model with the factors center,
period, treatment and patient within center. Multiplicity
issues were dealt with by a priori ordering of the hy-
potheses. Raw as well as adjusted least squares (LS)
means were provided as point estimates for all pair-wise
treatment contrasts. Non-inferiority of indacaterol to
tiotropium was to be demonstrated if the 95% confi-
dence interval for the mean inspiratory capacity differ-
ence of indacaterol minus tiotropium was entirely to the
right of (higher than) 150 mL. The superiority of indaca-
terol vs. placebo was tested first within the confirmatory
strategy for the full-analysis-set population. Once this
superiority had been established, non-inferiority of inda-
caterol vs. tiotropium was analysed. Then, in the third
step, superiority of indacaterol vs. tiotropium was tested.
As soon as one of this hypothesis could not be estab-
lished (i.e., the corresponding null-hypothesis failed to
be rejected), all following hypotheses were interpreted as
being purely exploratory and as not providing any
confirmatory evidence. For all pair wise comparisons,
the p-values from the primary ANOVA model were com-
pared to those obtained by applying a non-parametric
test (Wilcoxon signed rank) as supportive analysis. Sec-
ondary variables were analysed analogously to the pri-
mary endpoint.
Results
The baseline demographics and clinical characteristics
of all patients are given in Table 1. All patients were
Caucasians (67.4% male) with a mean age of 61.4 years
and a mean post-bronchodilator FEV1 of 64.0% predicted.
Of 129 patients screened, all were randomised and 110
(85.3%) completed the study. 19 patients discontinued due
to adverse events (4 events), abnormal laboratory value
(1 event), unsatisfactory therapeutic effect (3 events),
protocol deviation (3 events), consent withdrawal (5 pa-
tients) and administrative problems (3 events). One
patient discontinued the trial during the treatment period
with indacaterol, 6 patients during the placebo period, and
3 patients during the treatment with tiotropium.
Primary endpoint - peak IC
Mean peak IC at Day 21 was 2.69 L and 2.48 L with inda-
caterol and placebo, respectively. The LSM treatment
Table 1 Demographics and baseline characteristics
Total N = 129
Age (years) Mean (SD) 61.4 (8.9)
Sex–Male, Female, % 67.4, 32.6
Duration of COPD (years), Mean (SD) 6.2 (6.1)
Ex-smoker/smoker, % 46.5/53.5
Pack-years in ex-smokers, mean (SD) 41.1 (16.4)
Pack-years in smokers, mean (SD) 41.0 (16.7)
FEV1 pre-bronchodilator, L, mean (SD) 1.71 (0.58)
FEV1 post-bronchodilator, L, mean (SD) 1.90 (0.51)
FEV1 reversibility, % 10.26
FEV1% predicted (post-bronchodilator), mean (SD) 64.02 (9.38)
FEV1/FVC post-bronchodilator, % 58.98 (10.29)
FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
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defined criteria for superiority (p < 0.001) (Figure 1). The
significant differences observed by the ANOVA model
were confirmed by the results of the non-parametric Wil-
coxon test (difference indacaterol vs. placebo, p < 0.001).
Secondary endpoints - lung function
Mean peak IC at Day 21 was 2.69 L with indacaterol and
2.63 L with tiotropium (open-label) with the LSM treat-
ment difference (60 mL, 95% CI: -10–130) meeting the
criteria for non-inferiority (p < 0.001). Mean trough IC at
Day 20 was 2.39 L, 2.34 L and 2.23 L following treat-
ment with indacaterol, tiotropium, and placebo, respect-
ively (Figure 2). The results showed significant LSM
treatment differences versus placebo favoring indacaterolFigure 1 Effect of indacaterol and tiotropium versus placebo
on peak inspiratory capacity (IC) on Day 21. ***p < 0.001 vs
placebo; #non-inferiority to tiotropium. Data are least square mean ±
95% CI for FAS population (n = 129).(170 mL, 95% CI: 90–240; p < 0.001) and tiotropium
(110 mL, 95% CI: 30–190; p = 0.005). Lung volumes and
specific airway resistance demonstrated statistically sig-
nificant treatments effects of both bronchodilators com-
pared with placebo on both peak and trough values with
no significant treatment differences between indacaterol
and tiotropium (Table 2).
Peak FEV1 at Day 21 was 2.00 L, 1.99 L and 1.76 L
after indacaterol, tiotropium, and placebo treatment, re-
spectively. The mean difference versus placebo was
240 mL for both indacaterol (95% CI: 200–280, p <
0.001) and tiotropium (95% CI: 190–280, p < 0.001).
Trough FEV1 at Day 20 was 1.80 L, 1.78 L and 1.61 L
after treatment with indacaterol, tiotropium and placebo,
respectively (Table 2).
Exploratory endpoints - physical activity
Based on the prespecified reliability criteria with regard
to wearing time of the accelerometer (at least three days
of measurement with a recorded wearing time of at least
22 hours per day) complete datasets for the comparison
of physical activity during treatment with indacaterol
and placebo were available for 83 patients. Indacaterol
significantly increased the total number of steps per day
(7341; 95% CI: 6843–7838) compared with placebo
(6618; 95% CI: 6162–7074) by 722 steps per day (p =
0.019; Figure 3a). Minutes of at least moderate activity
per day were 125 min (95% CI: 106–145) during treat-
ment with indacaterol versus 97 min (95% CI: 79–115)
with placebo (p = 0.017; Figure 3b). Also the physicalFigure 2 Effect of indacaterol and tiotropium versus placebo in
trough inspiratory capacity (IC) on Day 20. ***p < 0.001 vs placebo;
#non-inferiority to tiotropium. Data are least square mean ± 95% CI
for FAS population (n = 129).
Table 2 Effect of indacaterol and tiotropium versus placebo on lung function
IND vs PBO TIO vs PBO
ITGV Peak -0.41 L p < 0.001; 95% CI: -0.54– -0.29 -0.38 L p < 0.001; 95% CI: -0.51– -0.25
Trough -0.27 L p < 0.001; 95% CI: -0.40– -0.14 -0.21 L p = 0.002; 95% CI: -0.35– -0.08
RV Peak -0.40 L p < 0.001; 95% CI: -0.54– -0.25 -0.39 L p < 0.001; 95% CI: -0.53– -0.25
Trough -0.32 L p = 0.001; 95% CI: -0.48– -0.15 -0.25 L p = 0.003; 95% CI: -0.42– -0.09
TLC Peak -0.16 L p = 0.021; 95% CI: -0.30– -0.03 -0.20 L p = 0.006; 95% CI: -0.34– -0.06
Trough -0.08 L p = 0.320; 95% CI: -0.23–0.07 -0.11 L p = 0.170; 95% CI: -0.26–0.05
IRV Peak 0.12 L p = 0.003; 95% CI: 0.04–0.19 0.08 L p = 0.049; 95% CI: 0.00–0.15
Trough 0.17 L p < 0.001; 95% CI: 0.09–0.25 0.11 L p = 0.005; 95% CI: 0.03–0.19
sRaw Peak -1.02 kPa*sec p < 0.001; 95% CI: -1.23– -0.81 -1.08 kPa*sec p < 0.001; 95% CI: -1.29– -0.87
Trough -0.81 kPa*sec p < 0.001; 95% CI: -1.00– -0.62 -0.63 kPa*sec p < 0.001; 95% CI: -0.83– -0.44
FEV1 Peak 0.24 L p < 0.001; 95% CI: 0.20–0.28 0.24 L p < 0.001; 95% CI: 0.19–0.28
Trough 0.19 L p < 0.001; 95% CI: 0.15–0.24 0.17 L p = 0.001; 95% CI: 0.13–0.22
ITGV, intrathoracic gas volume; RV, residual volume; TLC, total lung capacity; IRV, inspiratory reserve volume; sRaw, specific airway resistance; FEV1, forced
expiratory volume in one second.
a
b
Figure 3 Effect of indacaterol on physical activity during
treatment. (a) Steps per day (n=83) (b) Minutes of at least
moderate physical activity (n=83).
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with indacaterol (physical activity level, 1.61; 95% CI:
1.56–1.66) compared to placebo (physical activity level,
1.54; CI: 1.49–1.58) (p = 0.014). Further sensitivity ana-
lyses for the comparison of physical activity during treat-
ment with indacaterol and placebo in 77 patients, who
wear the accelerometer for at least 22 hours on at least
4 days, confirmed the significant differences between inda-
caterol and placebo (data not shown). A correlation be-
tween changes of IC and changes of any physical activity
parameter could not be demonstrated (data not shown).Safety
The overall incidence of adverse events was generally low
during treatment with indacaterol (24.6%), tiotropium
(20.2%) and placebo (20.0%) (Table 3). Five out of the 129
patients (3.9%) experienced serious adverse events (one
during treatment with indacaterol; one during treatment
with placebo; three during treatment with tiotropium) not
considered to be related to study treatment by the investi-
gator. No death occurred in any of the groups.Table 3 Adverse events overall and most commonly
occurring (≥2% of patients)
Indacaterol
(N = 118) n(%)
Tiotropium
(N = 119) n(%)
Placebo




Nasopharyngitis 9(7.6) 3(2.5) 8(6.7)
Back pain 2(1.7) 5(4.2) 2(1.7)
Headache 2(1.7) 2(1.7) 3(2.5)
Dyspnea 3(2.5) 1(0.8) 2(1.7)
Cough 4(3.4) 0(0.0) 0(0.0)
Rhinitis 2(1.7) 0(0.0) 0(0.0)
Hypotension 0(0.0) 0(0.0) 2(1.7)
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The main findings of the present study are that indaca-
terol and tiotropium provided significant improvements
in lung hyperinflation after three weeks of treatment,
and that physical activity measured by a multisensory ac-
celerometer was significantly improved during treatment
with indacaterol compared to placebo.
Lung hyperinflation may be more closely associated
with patient-reported symptoms like dyspnea and phys-
ical activity limitation than maximal expiratory flow
rates such as FEV1 [2,26]. The rationale behind the use
of long-acting bronchodilators is the sustained reduction
of lung hyperinflation with an increase of IC, which in
turn is related to an improvement of exertional dyspnea
and exercise intolerance in COPD [2,26]. Unlike FEV1, a
generally accepted minimal clinically important differ-
ence has not yet been identified for changes of IC fol-
lowing a therapeutic intervention, even though an
increase of 100 mL can be considered to be potentially
clinically meaningful [27]. The improvements of peak
and trough IC with both bronchodilators observed in
this study are in line with previously reported improve-
ments of IC for indacaterol and tiotropium [18,28,29].
The increase of peak IC after 21 days of treatment with
indacaterol 150 μg in the present study is slightly higher
than the increase of peak IC by 177 mL reported by
Rossi and colleagues after single administration of inda-
caterol 150 μg in moderate COPD [18] and the increase
of IC by 170 mL 75 min after the administration of inda-
caterol 300 μg following three weeks of treatment ob-
served in a recent study [28]. O’Donnell and colleagues
observed an increase of peak IC and trough IC of
250 mL and 100 mL, respectively after 21 days of treat-
ment with tiotropium 18 μg [28]. In another study Celli
and colleagues observed even higher increases of both
peak and trough IC following 4 weeks of treatment with
tiotropium 18 μg [29].
Comparing the improvements of FRC and RV ob-
served in our study with previously reported changes of
both lung volumes after treatment with indacaterol or
tiotropium it can generally be noted that the improve-
ments fit with previous studies [18,28,29]. Reduction of
FRC by about 300 mL and of RV by about 400 mL have
been reported after single administration of indacaterol
150 μg before. For tiotropium the observed changes of
FRC and RV in our study are in the range of previously re-
ported improvements following 21 days treatment [28,29].
While previous studies with tiotropium and indaca-
terol 300 μg demonstrated clear improvements of exer-
cise endurance time measured through constant-load
cycle ergometry testing [16,17,28] the effects of long-
acting bronchodilation on physical activity in daily life
are less studied so far, even though it is hypothesized
that the improvements observed by this laboratoryexercise test might also translate into an increase of
physical activity in daily life [3]. However, measuring the
physiological attributes that relate to the ability to per-
form physical activity might only indicate what a person
is capable of doing, whereas a measurement of physical
activity reflects what a person actually does, e.g. domes-
tic work, occupational activities, and leisure-time activ-
ities [30,31]. In the present study we were able to
demonstrate that physical activity measured by a multi-
sensory accelerometer improved during treatment with
indacaterol compared with placebo. Steps per day and
minutes of at least moderate activity per day significantly
improved by 10.9% and 29.2%, respectively. The im-
provement of the physical activity level from 1.54 during
placebo to 1.61 during treatment with indacaterol corre-
sponded to an increase of energy expenditure related to
physical activity by 12.9%. A minimal clinically import-
ant difference for changes of physical activity is not yet
available for patients with COPD. However, our results
can be discussed in the context of existing data with re-
gard to mortality that is associated with reduced levels
of physical activity. Waschki et al. demonstrated that the
decrease of the physical activity level by 0.14 and the de-
crease of 1845 steps per day in a cohort of patients with
mild to very severe COPD is associated with an increase
of the relative risk of death by 117% and 104%, respect-
ively [12]. Furthermore, recent data in healthy individ-
uals suggest that 15 min of moderate-intensity exercise
(e.g. brisk walking) a day is associated with 14% reduced
risk of all-cause mortality [32].
The improvements of physical activity observed in our
study confirm a recent open-label study with Indacaterol
[19]. Using a different type of accelerometer Hataji and
colleagues reported a significant increase of the number
of steps per day by 26%, duration of at least moderate
physical activity by 70%, and energy expenditure by 30%
during four weeks of treatment [19]. However, open-
label studies might be difficult to interpret in the context
of such a novel outcome variable like physical activity,
which might be highly influenced by behaviour and mo-
tivation [33]. This potential bias from an open label de-
sign brought us to the decision not to measure physical
activity in our study during open-label treatment with
tiotropium, while the lung function measurements might
be less affected by open-label therapy with tiotropium in
our study [34]. The effects of tiotropium on physical ac-
tivity are subject to a different trial [35].
A recent double-blind study with indacaterol 300 μg in
patients with moderate to severe COPD could not demon-
strate any changes of objectively measured physical activ-
ity, even though significant improvements of exercise
endurance time along with a decrease of IC could be ob-
served [17]. It is difficult to interpret the contrasting ob-
servations of both studies. One explanation could be that
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might impact the magnitude of response. Another explan-
ation for the significant effect on physical activity in our
study might be the higher number of included patients or
a more rigorous adjustment for wearing time. This, how-
ever, is clearly subject to speculation and further studies
have to confirm our findings.
Conclusion
To conclude this study demonstrated the benefit of
indacaterol 150 μg on static lung hyperinflation, which
was similar to the effects of tiotropium. This study also
showed the beneficial effects of bronchodilator treatment
with indacaterol on physical activity in daily life in patients
with moderate COPD.
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